Sylvester Comprehensive Cancer Center

  • TAPUR - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone 3052431481

    IRB: 20170529

    SDG: Breast Cancer
    Disease Site(s):

    Breast,Prostate,Kidney,Non-Hodgkin Lymphoma,Multiple Myeloma,Lymphoid Leukemia,Colon,Liver,Pancreas,Larynx,Soft Tissue,Kaposis sarcoma,Multiple

    Sponsor: ASCO

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190759 - Feun Lynn

  • Investigator:
    Lynn Feun
    RCname Email

    Coordinator:

    IRB: 20190759

    SDG: Cutaneous Malignancies
    Disease Site(s):

    Melanoma, skin

    Sponsor: SWOG

    Enrolling Sites:

    Sylvester

    Title:

    A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma

    Eligibility Criteria - NCT03698019 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190962 - Feun Lynn

  • Investigator:
    Lynn Feun
    RCname Email

    Coordinator:

    IRB: 20190962

    SDG: Cutaneous Malignancies
    Disease Site(s):

    Melanoma, skin

    Sponsor: IMMUNOCORE LIMITED

    Enrolling Sites:

    Sylvester

    Title:

    A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma

    Eligibility Criteria - NCT03070392 *This information has been extracted from " www.clinicaltrials.gov"

  • C-610-01 - Hosein, Peter

  • Investigator:
    Peter Hosein
    RCname Email

    Coordinator:
    RCemailImg Alexander Diaz
    RCphone 3052436855

    IRB: 20180763

    SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Breast,Bladder,Rectum,Soft Tissue,Melanoma, skin

    Sponsor: Agenus

    Enrolling Sites:

    Sylvester

    Title:

    C-610-01:A Phase 1a First-in-Human Study of Safety and Tolerability of ASV? AGEN2017 With QS-21 Stimulon« Adjuvant as a Single Agent in Subjects with Solid Tumor at Risk of Relapse Undergoing Observation as Standard of Care Following Complete Surgical Resection

    Eligibility Criteria - NCT03673020 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190822 - Hosein Peter

  • Investigator:
    Peter Hosein
    RCname Email

    Coordinator:
    RCemailImg Alexander Diaz
    RCphone 3052436855

    IRB: 20190822

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Ovary,Prostate,Stomach,Colon,Rectum,Pancreas,Other Digestive Organ,Lung,Melanoma, skin

    Sponsor: NGM BIOPHARMACEUTICALS

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

    Eligibility Criteria - NCT04068896 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191076 - Hosein Peter

  • Investigator:
    Peter Hosein
    RCname Email

    Coordinator:

    IRB: 20191076

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Breast,Prostate,Bladder,Kidney,Other Urinary,Thyroid,Non-Hodgkin Lymphoma,Hodgkin Lymphoma,Stomach,Small Intestine,Colon,Rectum,Anus,Liver,Pancreas,Other Digestive Organ,Soft Tissue,Melanoma, skin

    Sponsor: EISAI

    Enrolling Sites:

    Sylvester

    Title:

    An Open-Label, Multicenter Phase 1/1b Study of Intratumorally Administered STING Agonist E7766 in Subjects With Advanced Solid Tumors or Lymphomas ? INSTAL-101

    Eligibility Criteria - NCT04144140 *This information has been extracted from " www.clinicaltrials.gov"

  • VYR-VSV2-101 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Rakhi Modak
    RCphone 3052437387

    IRB: 20170023

    SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Lung,Melanoma, skin,Kaposis sarcoma

    Sponsor: VYRIAD

    Enrolling Sites:

    Sylvester

    Title:

    Phase I Trial of Intratumoral Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and human interferon beta (VSV-IFN▀-NIS), in Patients with Refractory Solid Tumors

    Eligibility Criteria - NCT02923466 *This information has been extracted from " www.clinicaltrials.gov"

  • RPL-001-16 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone 3052438227

    IRB: 20180802

    SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Bladder,Colon,Breast-Female,Melanoma, skin

    Sponsor: REPLIMUNE

    Enrolling Sites:

    Sylvester

    Title:

    RPL-001-16: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors

    Eligibility Criteria - NCT03767348 *This information has been extracted from " www.clinicaltrials.gov"

  • PISCES - Moller, Mecker

  • Investigator:
    Mecker Moller
    RCname Email

    Coordinator:

    IRB: 20170513

    SDG: Cutaneous Malignancies
    Disease Site(s):

    Melanoma, skin

    Sponsor: ONCOSEC

    Enrolling Sites:

    Sylvester

    Title:

    A Multicenter Phase 2, Open-Label Study ofIntratumoral Tavokinogene Telseplasmid (tavo, pIL-12) plusElectroporation in Combination with Intravenous Pembrolizumabin Patients with Stage III/IV Melanoma who are Progressing oneither Pembrolizumab or Nivolumab Treatment

    Eligibility Criteria - NCT03132675 *This information has been extracted from " www.clinicaltrials.gov"

  • C-500-01 - Perez, Cesar

  • Investigator:
    Cesar Perez
    RCname Email

    Coordinator:
    RCemailImg Chinar Singh
    RCphone 3052438237

    IRB: 20160238

    SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Brain and Nervous System,Leukemia, Other,Bones and Joints,Melanoma, skin

    Sponsor: Agenus

    Enrolling Sites:

    Sylvester

    Title:

    C-500-01

    Eligibility Criteria - NCT02694822 *This information has been extracted from " www.clinicaltrials.gov"

  • AST-008-102 - Perez, Cesar

  • Investigator:
    Cesar Perez
    RCname Email

    Coordinator:
    RCemailImg Chinar Singh
    RCphone 3052438237

    IRB: 20180957

    SDG: Head and Neck Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Bones and Joints,Melanoma, skin

    Sponsor: EXICURE INC

    Enrolling Sites:

    Sylvester

    Title:

    AST-008-102 :A Phase 1b/2 Study of AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors

    Eligibility Criteria - NCT03684785 *This information has been extracted from " www.clinicaltrials.gov"

  • MATCH - Slomovitz, Brian

  • Investigator:
    Brian Slomovitz
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone 3052431481

    IRB: 20150671

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Corpus Uteri,Ovary,Other Female Genital,Prostate,Kidney,Non-Hodgkin Lymphoma,Multiple Myeloma,Colon,Liver,Pancreas,Larynx,Soft Tissue,Kaposis sarcoma

    Sponsor: ECOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester

    Title:

    Molecular Analysis for Therapy Choice (MATCH)

    Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"

  • 20180174 - Tiozzo Eduard

  • Investigator:
    Eduard Tiozzo
    RCname Email

    Coordinator:

    IRB: 20180174

    SDG: Population Sciences
    Disease Site(s):

    Melanoma, skin

    Sponsor: SCCC

    Enrolling Sites:

    Sylvester

    Title:

    Feasibility and Safety Profile of a 3-month Aerobic and Resistance Exercise Intervention for Individuals Diagnosed with Melanoma

    Eligibility Criteria - NCT03825913 *This information has been extracted from " www.clinicaltrials.gov"